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Prostate cancer is one of the most common cancers in European
and American males and has a high mortality rate (Landis et al,
1998; Rosenthal, 1998). Early disease is managed conservatively
in Europe although in selected patients surgery is curative. In
advanced disease, androgen ablation can produce symptomatic
improvement, but the tumour often re-emerges in an androgen-
independent and incurable form. One proposed treatment for
androgen-independent prostate carcinoma is differentiation ther-
apy, in which agents such as all-trans-retinoic acid (ATRA), 9-cis-
retinoic acid and 1a, 25-dihydroxyvitamin D3 (D3) are used to
induce growth arrest, differentiation and sometimes apoptosis of
the tumour cells (Liang et al, 1999; de Vos et al, 1997; Skowronski
et al, 1994; Hedlund et al, 1997). 
ATRA and synthetic analogues exert their biological effects by
binding to two families of retinoid receptors, the RARs (RARa,
RARb and RARg) and the RXRs (RXRa, RXRb and RXRg). These
are ligand-dependent transcription factors of the steroid/thyroid
hormone nuclear receptor superfamily (Chambon 1994; Boehm
et al, 1995). Activated RARs bind to retinoic acid-responsive
elements (RAREs) in the promoters of genes and thus regulate
gene expression. They also antagonize the activity of the tran-
scription factor AP1 and thereby down-regulate the expression of
some AP1-activated genes (Nagpal et al, 1995). One approach to
unravelling the contributions of RAR sub-types to these actions
has been the development of synthetic retinoids with selective
activities at individual RARs and RXRs. For example, the diaryl-
acetylenic retinoids allow separation of transactivation and AP1
antagonism functions at RARa (Nagpal et al, 1995). Recently,
compounds that are selective for particular RAR sub-types have
been synthesized: these include both agonists and antagonists
(Chandraratna, 1995; Teng et al, 1999; Johnson et al, 1999). The
functional selectivity of these compounds may open the way
to achieving differentiation or apoptosis of tumour cells with
minimal systemic side effects (Chandraratna, 1995). 
Cell lines that are commonly used in the evaluation of investiga-
tional agents for prostate cancer include LNCaP, DU-145 and PC-
3. LNCaP cells are androgen-responsive and express RARa,
RARb and RARg, whereas DU-145 and PC3 cells are androgen-
insensitive and do not express RARb (Campbell et al, 1998).
These lines are relatively insensitive to growth inhibition and
induction of apoptosis by ATRA and by synthetic agonists. ATRA
induces apoptosis of LNCaP cells at 2 mM (Gao et al, 1999), but
neither inhibits the growth nor induces apoptosis of PC-3 and DU-
145 cells at 2 mM (Lu et al, 1997 and 1999). Fenretinide (4HPR)
induces apoptosis of LNCaP and of PC-3 cells at 1–5 mM and 25
mM, respectively (Pienta et al, 1993; Heish and Wu, 1997). Pfahl
and colleagues examined the growth inhibitory effects of a panel
of receptor-selective retinoids against DU145 and PC-3 cells and
achieved complete growth inhibition and induction of apoptosis
between 1 mM and 10 mM (Lu et al, 1999). They screened more
than 100 retinoids for growth-inhibitory activity against prostate
carcinoma lines: three RARg agonists were the most active (Lu
et al, 1999). 
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doi: 10.1054/ bjoc.2001.1939, available online at http://www.idealibrary.com on  http://www.bjcancer.comIn this study, we have investigated the extent to which synthetic
retinoids directed against RAR sub-types inhibit the growth of
prostate carcinoma cell lines. These compounds included agonists
of RARa and RARbg and antagonists of RARa, RARbg and
RARabg. In our screens we have used sub-lines of LNCaP, PC-3
and DU145 cells that had been grown long-term in serum-free
conditions: the development and characteristics of these lines are
described. The use of serum-free grown lines avoids the complica-
tion introduced by the small amounts of naturally occurring
retinoids in serum. We find that RAR antagonists are substantially
more potent than agonists in inducing growth arrest both of
prostate carcinoma cell lines and of primary prostate carcinoma
cultures. As such, they are potentially useful in prostate cancer
therapy. 
MATERIALS AND METHODS 
Retinoids 
The novel synthetic RAR ligands were synthesized at Allergan
Inc. (Irvine, CA). Their structures are shown in Table 1. They
comprise RARa agonists (AGN194078, AGN195153), a RARbg
agonist (AGN190299) (Nagpal et al, 1995), a specific RARa
antagonist (AGN194301) (Teng et al, 1999), an RARbg antagonist
(AGN194431) and an RAR pan-antagonist (AGN194310)
(Johnson et al, 1999). Our definition of the term RAR antagonist is
a compound that binds to the RARs (see Table 1) and that does not
activate gene transcription (see Table 1) but instead blocks the
gene transcriptional activity induced by ATRA and other RAR
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Table 1 Structures of novel retinoid analogues, and their receptor binding and transactivation properties 
RARa RARb RARg
Compound no. (AGN) Structure Receptor Specificity1 Kd
2 (nM) EC50
3 (nM) Kd
2 (nM) EC50
3 (nM) Kd
2 (nM) EC50
3 (nM)
194078 RARa agonist 4 140 > 5000 WA > 5000 NA4
195153 RARa agonist 40 130 > 5000 WA > 5000 WA4
190299 RARbg agonist 616 > 1000 41 18 57 42 
194310 RARabg antagonist 3 NA4 2N A 4 5N A 4
194301 RARa antagonist 3 NA4 320 NA4 7250 NA4
194431 RARbg antagonist 300 NA4 6N A 4 70 NA4
1When tested against RXRa, RXRb and RXRg, all compounds were inactive: Kd values for binding were >10 mM, and they showed no activity in transactivation
assays. 2Binding to baculovirus-expressed RARa, RARb and RARg was measured. 3EC50 values for transactivation by RARs were determined by doubly
transfecting CV-1 cells (500 cells/well) with an RAR reporter plasmid (DMTV-TREp-LUC) and one of the human RAR expression vectors, and then treating the
transfected cells with the defined ligand (Nagpal et al, 1995). 4Abbreviations: NA, inactive; WA, weak partial agonist. 
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COOHagonists (Johnson et al, 1999). All the above compounds, the pan-
RAR agonist TTNPB ((E)-4-[2-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-
tetramethyl-2-naphthalenyl-1-propenyl]-benzoic acid) and ATRA
were stored as 10 mM stock solutions in 50% ethanol/50%
dimethysulphoxide at –20˚C. Control cultures contained the
solvent alone. 
Establishment of serum free-grown stocks of prostate
carcinoma cell lines 
The prostate carcinoma cell lines LNCaP, PC-3 and DU-145 were
from the American Type Culture Collection (ATCC, Rockville,
MD) and maintained in RPMI 1640 medium (Gibco-BRL, Paisley,
UK) supplemented with 10% fetal bovine serum (FBS, Gibco),
100 U/ml penicillin and 100 mg/ml streptomycin. Cells were
grown at 37˚C in a humidified atmosphere of 5% CO2 in air and
passaged by trypsinizing with trypsin-EDTA (Gibco-BRL). 
Serum grown LNCaP, PC-3 and DU-145 (FBS cells) were
adapted to growth in serum-free conditions by replacing half of the
medium at each medium change and passage with RPMI 1640
medium containing antibiotics (as above) and supplemented with
insulin, transferrin, selenium dioxide, linoleic acid, and bovine
serum albumin (ITS+, Sigma, Poole, UK). All three lines readily
adapted to growth under serum-free conditions (ITS+ cells)
without adverse effects on cell growth, viability and adherence.
Serum and serum-free grown lines were sub-cultured in a similar
manner. Following trypsinization of the serum-free grown lines,
trypsin was inactivated using ITS+ medium. 
Growth of primary prostate carcinoma cells 
Core biopsies were obtained from patients undergoing investiga-
tion for suspected prostatic carcinoma. Consent for the use of this
material for research purposes was obtained from the Local
Research Ethics Committee and from the patients. Histological
examination confirmed that the biopsies contained tumour mate-
rial. Cultures were established essentially as described by Peehl
and co-workers (Peehl et al, 1991), using the serum-free medium
Prostate Epithelial Cell Growth Medium (PrEGM) supplemented
with SingleQuots (Biowhittaker, Wokingham, UK). Cells were
sub-cultured onto plates coated with collagen-1 (Greiner,
Stonehouse, UK), and these plates and the above medium were
used for assays. 
Analysis of the effects of retinoids on cell growth 
In the clonal proliferation assay, single-cell suspensions of cells were
plated at 400 (FBS cells) and 1200–1500 (ITS+ cells) cells per 65
mm2 dish in 4 ml of medium. The difference in the number of cells
plated takes into account the lower cloning efficiency of the serum-
free grown cells (see Results section). Retinoids (10–9–10– 6 M) were
added immediately and the medium plus retinoids were replaced at
day 2. Plates were incubated (see above) for 14 days (serum-free
grown cells) or 9 days (serum-grown cells), fixed using 1%
formaldehyde in 0.9% NaCl, stained with 1% methylene blue in
0.9% saline and allowed to dry. Around 200 colonies were counted
on each plate. Colony size was variable and the minimum number
of cells in a cluster regarded as a colony was 70. When agents had
blocked colony formation, even very small clusters of cells were
not visible on the plates. Plates were set up in duplicate, and at
least three experiments of each type were performed. Colony
formation on agent-treated plates is presented as a percentage
(mean ± SE) of the number of colonies on untreated plates. Vehicle
alone had no effect on colony formation (see Results). 
To further characterize the effect of the pan-RAR antagonist
AGN194310 on LNCaP ITS+ cells, bulk cultures were seeded at
2–5 ´ 105 cells per 75 cm2 flask. AGN194310 was added immedi-
ately and at day 2. Adherent cells were harvested by trypsinization,
pooled with those in suspension, and counted. 
Measurements of cell cycle status and of apoptosis 
Cells, harvested by trypsinization, were stained with propidium
iodide and the distribution of cells within phases of the cell cycle
was determined using a Becton-Dickinson Flow Cytometer and
CellFIT Cell-Cycle Analysis software. Apoptotic cells were iden-
tified, within pooled adherent and suspension cells, by the TUNEL
assay (Gorczyca et al, 1993). A FITC-conjugated antibody to
bromodeoxyuridine (Becton-Dickinson & Co., Mountain View,
CA) was used to identify cells labelled with bromodeoxyuridine
triphosphate and green fluorescence was measured by FACS
analysis at 510–550 nm. 
Immunodetection of RARs in ITS+-grown cells 
Cell pellets were resuspended in lysis buffer (2% (w/v) SDS, 
60 mM Tris-HCl (pH 6.6), 5 mM EDTA, 10 mM DTT, 1 mM
PMSF) and boiled for 10 min. Samples (90 mg) were elec-
trophoresed on 12% SDS-PAGE gels, electroblotted to Hybond-
ECL membranes (Amersham Life Sciences, Bucks, UK) and probed
using polyclonal antibodies to RARa, RARb, and RARg, diluted
1/1000 (kindly provided by P. Chambon (RARa) and Santa Cruz
Biotechnology Inc. Wembley, Middlesex, UK (RARb and RARg)).
Blots were visualized by enhanced chemiluminescence using an
HRP-conjugated secondary antibody (Amersham Life Sciences). 
Statistical analysis 
The effects of individual agents on colony formation were
compared to control untreated and vehicle treated cultures using
the Student’s t-test. 
RESULTS 
Binding and transactivation properties of retinoids 
Table 1 summarizes RAR binding and transactivation by the
retinoids investigated for activity against prostate carcinoma
cells. None of the compounds bound to baculovirus-expressed
RXRa, RXRb and RXRg (Kd > 10 K) or transactivated an RXR-
responsive promotor construct (human CRBP II promotor DR1
elements) in the presence of RXR expression vectors (data not
shown). Selectivity of analogues at RAR receptor subtypes was
shown by in vitro binding experiments, using baculovirus-
expressed RARa, RARb and RARg. Similar selectivity was
observed in the RARa, RARb and RARg transactivation assays. 
The RAR antagonists are of particular interest in this study
(see below). AGN194310 is a pan-antagonist that binds to
RARa, RARb and RARg with equal and high affinities (Kd =
2–5 nM). AGN194301 is a high affinity RARa antagonist (Kd =
3 nM); AGN194431 is RARbg-selective, and binds more
strongly to RARb (Kd = 6 nM) and RARg (Kd = 70 nM) than to
RAR antagonism in prostate cancer 455
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in a model system, we investigated their effects on ATRA-induced
differentiation of HL60 cells to neutrophils (Breitman et al, 1980).
HL60 cells express RARa, and treatment with 100 nM ATRA for 5
days gave rise to 64 ± 5% neutrophils that displayed stimulated
nitroblue tetrazolium reduction. AGN194310 (a pan-RAR antago-
nist) and AGN194301 (a RARa antagonist), added at 100 nM,
prevented ATRA-induced neutrophil differentiation: the percent-
ages of mature cells were 5% (AGN194310) and 1%
(AGN194301). 
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Figure 1 RAR antagonists block colony formation by serum free-grown prostate carcinoma lines, but are less effective against serum-grown cells. Compounds
were screened, all at 100 nM, for their ability to inhibit plate colony formation by serum free (ITS+)- and serum (FBS)-grown LNCaP, DU145 and PC3 cells. 
Data obtained for compounds of identical receptor specificity were similar and have been combined. The compounds tested were: ATRA; RARa agonists,
AGN194078 & AGN195153; RARbg agonists AGN190168 & AGN190299; pan-RAR antagonist AGN194310 and RARa antagonist AGN194301. 
Data (means ± SE) are presented as a percentage of the number of colonies on untreated plates Characterization of ITS+-grown LNCaP, PC3 and DU145
prostate carcinoma lines 
To prevent naturally occurring retinoids and other ligands from
masking the effects of added retinoids, we developed serum-free
stocks of the prostate carcinoma lines. These ITS+ lines have been
maintained serum-free for ~3 years and are identical in appearance
to their counterparts grown in FBS. ITS+ and FBS stocks grow
with similar doubling times: 24 ± 4 h (ITS+) vs 24 ± 1 h (FBS) for
LNCaP cells; 21 ± 1 h (ITS+) vs 29 ± 2 h (FBS) for DU145 cells;
17 ± 1 h (ITS+) vs 20 ± 1 h (FBS) for PC3 cells. Each ITS+ line has
a lower cloning efficiency in the plate colony assay than its FBS
counterpart. The percentage cloning efficiencies are: LNCaP 
cells, 13 ± 1 (ITS+) vs 19 ± 2.9 (FBS); DU145 cells, 10 ± 1 (ITS+)
vs 15 ± 2 (FBS); and PC3 cells, 7 ± 1 (ITS+) vs 11 ± 2 (FBS). 
The ITS+ cells expressed the same RAR receptors, determined
by Western analysis, as the parental FBS cells. LNCaP cells ex-
pressed RARa, RARb and RARg and DU145 and PC3 cells
expressed RARa and RARg (data not shown, and Campbell et al,
1998). FBS-grown prostate carcinoma cell lines are reported to be
relatively insensitive to growth inhibition by ATRA (de Vos et al,
1997; Lu et al., 1997; Gao et al., 1999; Lu et al., 1999), and we
confirmed this for ITS+-grown and FBS-grown cells. A 50% inhi-
bition of colony formation by the ITS+ cells was attained at 344 ±
32 nM ATRA for LNCaP, 402 ± 74 nM ATRA for DU145 and 419
± 120 nM ATRA for PC3. Only modest inhibition of colony
formation was observed with FBS-grown cells at 1 mM ATRA;
reductions in colony formation by LNCaP, DU145 and PC3 cells
were 49 ± 6%, <1% and 33 ± 7%, respectively. 
RAR antagonists inhibit colony formation by 
ITS+-grown prostate carcinoma lines 
When compounds were screened, all at 100 nM, for their ability to
inhibit colony formation, the most striking inhibition occurred
when ITS+-grown cells were treated with the pan-RAR antagonist
AGN194310 (Figure 1). Colony formation was reduced to 3–7%
of control values in all three cell lines. AGN194310 inhibited
colony formation by FBS-grown cells by only 11–23%. The
RARa-specific antagonist AGN194301 also inhibited colony
formation by the three prostate lines when grown in ITS+ medium
(by 42–74%), but had little effect on FBS-grown cells (0–19%
inhibition). Treatment of the three cell lines (ITS+ and FBS cells)
with ATRA, RARa agonists and a RARbg agonist had little effect
RAR antagonism in prostate cancer 457
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Figure 2 A pan-RAR antagonist is a potent inhibitor of colony formation by
serum-free grown prostate carcinoma cells. A pan-RAR antagonist
AGN194310 (diamonds), an antagonist of RARbg AGN194431 (inverted
triangles), an antagonist of RARa AGN194301 (triangles), ATRA (circles) and
appropriate vehicle controls (squares) were titrated against ITS+-grown
LNCaP, DU145 and PC3 cells using the plate clonogenic assay. The effects
of retinoids and vehicles are presented as a percentage of the number of
colonies observed on untreated plates. Data are the means ± SE of values
from at least three separate replicate experiments 
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Figure 3 A pan-RAR agonist counteracts the growth inhibitory effect of the
pan-RAR antagonist. The pan-RAR agonist TTNPB was titrated, against
LNCaP ITS+-grown cells using the plate clonogenic assay, alone (circles) and
in combination with 50 nM (triangles) and 100 nM (squares) of the pan-RAR
antagonist AGN194310. The hatched lines show the inhibitory effects of 
the two doses of AGN194310 alone. Data are presented as a percentage 
of the number of colonies observed on untreated plates and are the means ±
SE of values from at least three separate replicate experiments on colony formation (Figure 1). LNCaP ITS+ and DU-145 ITS+
cells showed a very slight increase (~17% and 13%, respectively)
in colony formation post-treatment with the RARa agonists.
However, statistical analysis of the actual number of colonies
seen on control (untreated) vs agonist-treated plates revealed
that an increase in colony formation only approached significant
in the case of LNCaP ITS+ cells (P = 0.15) and was not signifi-
cant in the case of DU-145 ITS+ cells (P = 0.8). 
To exclude the possibility that the inhibitory effects of the antago-
nists are merely cytotoxic effects on all targets, we tested whether
the pan-RAR antagonist AGN194310 and the RARa-specific
antagonist AGN194301 interfere with the clonal growth of the
promyeloid cell line HL60 (Wallington et al, 1996). Serum-free
grown HL60 cells (>7 years) were plated as single cells in microtitre
wells and treated with 100 nM of the above agents. The number of
viable cells was enumerated daily for 4 days. AGN194310 and
AGN194301 did not adversely affect the clonal growth of HL60
cells; the cloning efficiencies of untreated and antagonist-treated
cultures were the same (90–93%, and see Wallington et al, 1996).
Additionally, the numbers of viable cells, at day 4, in control (n =
78), AGN194310-treated (n = 65) and AGN194301-treated (n = 67)
cultures were 18, 17 and 22, respectively. Viabilities of the single
cells in all three conditions were >95%. 
We therefore focused our attention on inhibition of colony
formation by ITS+-grown LNCaP, PC3 and DU-145 cells by RAR
antagonists. Figure 2 shows dose-response curves for the pan-
RAR antagonist (AGN194310) and for antagonists of RARbg
(AGN194431) and of RARa (AGN194301). Once again,
AGN194310 potently inhibited colony formation by all three
lines, with IC50 values of 16 ± 5 nM for LNCaP cells; 18 ± 6 nM
for PC3 cells; and 34 ± 7 nM for DU-145 cells. The RARbg
antagonist AGN194431 was less potent than AGN194310: IC50
values were 99 ± 10 nM for LNCaP cells, 104 ± 2 nM for PC3
cells and 88 ± 12 nM for DU145 cells. The RARa antagonist
AGN194301 was the least potent; IC50 values were 203 ± 36 nM
(LNCaP), 235 ± 20 nM (PC3) and 201 ± 23 nM (DU145). 
The pan-RAR agonist TTNPB counteracts the growth
inhibitory effect of the pan-RAR antagonist AGN 
194310 
In these experiments, we used the non-metabolized RAR agonist
TTNPB to avoid any influence of down-stream metabolites.
TTNPB, when used alone at concentrations up to 10 –7 M, had only
a small inhibitory effect on the clonal growth of LNCaP ITS+ cells
(~10% inhibition at 10 –7 M, see Figure 3). A higher concentration
of TTNPB (10 –6 M) inhibited colony formation (by >90%). The
pan-RAR antagonist AGN194310 was tested for its ability to inhibit
colony formation at concentrations of 50 nM and 100 nM alone and
in combination with 10 –7 to 10 –14 M TTNPB. As shown in Figure 3,
50 nM and 100 nM AGN194310 inhibited colony formation to 41%
and 14% of control values, respectively. When this agent was used
together with 100 nM TTNPB, there was almost complete reversal
of the growth inhibitory effect of 50 nM AGN194310 (see Figure 3)
and partial reversal of the effect of 100 nM AGN194310 (colony
formation increased from 14% to 40% of control values). This
reversal, together with the finding that RAR antagonists block
agonist-induced differentiation of HL60 cells (see above), show that
antagonists are binding to and mediating their effects via RARs. 
RAR antagonism causes cells to accumulate in G1 and
undergo apoptosis 
Eighty percent (±11%) growth inhibition of cells grown in flasks
for 3 days was achieved by treatment with 1 mM AGN194310
458 LA Hammond et al
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Figure 4 Pan-antagonism of RARs leads to a rise in the proportion of G1
cells followed by apoptosis. Data obtained for the effect of 1 mM of the 
pan-antagonist AGN194310 on viable cell numbers are presented as a
percentage of the cells present in untreated flask cultures of ITS+-grown
LNCaP cells (4A). The proportions of pan-antagonist-treated (diamonds) and
untreated (circles) cells in each phase of the cell cycle were determined by
propidium iodide staining and flow cytometry (4B). Apoptotic cells were
identified by TdT end-labelling and flow cytometry (4C). Data are the 
means ± SE of values from triplicate experiments (Figure 4A). Analysis of cell cycle status by propidium iodide
labelling revealed a transient increase, at day 1, in the proportion
of G1 cells from a control value of 62 ± 4% to 71 ± 2% for
AGN194310-treated cultures (Figure 4B). The proportion of cells
in S phase decreased from 22 ± 2% (control cultures) to 15 ± 3%
(AGN194310-treated). By day 3, a substantial proportion of the
pan-antagonist-treated cells had detached from the flask and were
undergoing apoptosis (20 ± 9% vs. 3 ± 1% in control cultures),
as shown by TdT end-labelling and FACS analysis (Figure 4C). 
A component(s) of serum and of LNCaP-conditioned
medium blocks the growth-inhibitory effect of RAR
antagonists on ITS+-grown cells 
Our results indicated that FBS-grown and ITS+-grown cells were
either intrinsically different in their sensitivities to RAR antago-
nists or a serum component blocked the action of these agents. To
investigate the latter possibility, we measured inhibition of colony
formation when ITS+-grown LNCaP cells were plated in FBS
medium. Plating ITS+-grown cells in 10% and 20% FBS medium
modestly stimulated colony formation (by 15 ± 8% in 10% FBS
and by 30 ± 8% in 20% FBS). The addition of serum to ITS+-
grown LNCaP cells partially reversed the inhibition of colony
formation by AGN194310. Colony formation was <1% when ITS+
cells were plated in ITS+ medium and treated with 100 nM
AGN194310, and was restored to 48 ± 6% and 69 ± 6% by the
presence of 10% FBS and 20% FBS, respectively (Figure 5A).
Similarly, treatment of LNCaP ITS+-grown cells in ITS+ medium
with the RARa antagonist AGN194301 (100 nM) inhibited colony
formation by 69 ± 16% and colony formation was restored to 55 ±
16% and 119 ± 5% of control values respectively, by addition of
10% or 20% FBS. 
When analysing growth inhibition by AGN194310, it became
apparent that a higher concentration (1 mM) was required to attain
maximum growth inhibition of the flask cultures than of the fewer
cells plated in the colony assay (100 nM). To investigate whether
LNCaP cells might produce something that interferes with the
action of the antagonist, we determined whether conditioned
medium from exponentially growing LNCaP ITS+ cultures could
block the growth inhibitory effect of AGN194310. Figure 5B
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blocks pan-antagonist-mediated inhibition of colony formation. (A) shows that
plating LNCaP ITS+ cells in 10% and 20% FBS stimulates colony formation
and that the inhibitory effect of 100 nM of the pan-RAR antagonist
AGN194310 is partially blocked. (B) shows that conditioned medium from
exponentially growing cultures of LNCaP ITS+ cells stimulates colony
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Figure 6 The pan-RAR antagonist is more potent that ATRA in inhibiting
growth of primary prostate carcinoma cells. Bulk cultures of carcinoma cells
from core biopsies of two patients with prostatic carcinoma were treated on
day 0 with either 10 and 100 nM of the pan-RAR antagonist AGN194310, 10
and 100 nM ATRA or vehicles for these two agents. On days 3 (ATPrC) and
6 (WBPrC), adherent cells were harvested, pooled with any suspension cells
and viable cells were counted. Agent effects are presented as a percentage
of the number of viable cells in untreated cultures. Data are from single
experiments with duplicate cultures and the means of values are shown. shows that plating the LNCaP ITS+ cells in LNCaP-conditioned
medium abrogated the growth inhibitory activity of AGN194310.
This effect was concentration-dependent, with half-maximal
reversal of the inhibition at a 1:10 dilution of the conditioned
medium (Figure 5B). 
Insulin-like growth factor-1 (IGF-1) is one serum component
that has been reported by Pietrzkowski and collegues to be
produced by LNCaP, PC-3 and DU145 cells grown in serum-free
medium. These workers have proposed that these cells grow by an
autocrine loop in which overproduced IGF-1 activates its receptor
(Pietrzkowski et al, 1993). Other investigators have identified
elevated plasma IGF-1 as a predictor of prostate cancer risk (Chan
et al, 1998; Manztzoros et al, 1997). In our hands, the long R3
form of IGF-1 (0.1–100 ng/ml) (Gropep, Adelaide, Australia),
which does not bind to IGF binding proteins, had no effect on
colony formation by LNCaP ITS+ cells, with or without 100 nM
AGN194310 (see Figure 5C). The IGF-1 used was biologically
active: it stimulated growth of the breast carcinoma line MCF-7 in
10% charcoal-stripped serum by 64 ± 27% (Xie et al, 1997). Long
R3-IGF-1 also slightly stimulated the growth of FBS-grown
LNCaP cells in charcoal-stripped serum (by 23 ± 5%). 
Epidermal growth factor (EGF)-mediated signalling is also
thought to be a key autocrine regulator of growth in prostate
cancer and EGF stimulates the growth of LNCaP and DU-145
cells under serum-free conditions (Sherwood et al, 1998). EGF
(at 1, 10 and 20 ng/ml) (R & D, Abingdon, UK) did not reverse the
inhibition of colony formation by 100 nM AGN194310 (>95%
inhibition), but did stimulate the growth of FBS-grown LNCaP
cells in charcoal-stripped serum (by 25 ± 5%). 
AGN194310 inhibits the growth of primary prostate
carcinoma cells 
We established primary cultures of carcinoma cells from core
biopsies of two patients with prostatic carcinoma. Cultures had
epithelial morphology, confirmed by immunocytochemical
staining for cytokeratins and prostate-specific antigen, and
contained few contaminating fibroblasts. Flask cultures of these
cells were tested, at passage 2, for their sensitivity to AGN194310
and to ATRA. Cell growth in vehicle-treated and ATRA-treated
cultures was similar to controls. However, treatment of both
primary lines with AGN194310 (10 and 100 nM) caused substan-
tial growth inhibition (see Figure 6). 
DISCUSSION 
RAR antagonists potently inhibit the growth of three prostate
carcinoma cell lines; the most potent was a pan-RAR antagonist
(AGN194310), followed by an antagonist with predominant
activity at RARbg (AGN194431) and the RARa antagonist
(AGN194301). The pan-RAR antagonist AGN194310 was 12–22-
fold more potent than ATRA. However, growth inhibition at low
antagonist concentrations was only observed using cells that were
grown in the absence of serum. Fanjul and co-workers have shown
that RAR antagonists (three compounds) inhibit the growth of
breast carcinoma lines more potently than ATRA, but only in low
serum (0.5%) conditions (Fanjul et al, 1998). Their most potent
compound was MX781, a pan-RAR antagonist, which abolished
cell proliferation at >1 mM. AGN194310 appears to be more
potent than MX781 against carcinoma cells since it largely
prevents colony formation at 100 nM. In our studies, and those of
Fanjul and co-workers, the growth inhibitory activities of ATRA
and of agonists selective for RARa and for RARbg were similar
when cells were grown serum-free or in 0.5% FBS vs 10% FBS. 
At which RAR subtype(s) does antagonism compromise the
growth and survival of prostate carcinoma cells? Table 2 summa-
rizes IC50 and Kd values for antagonists and the RAR types
expressed by the cell lines. PC-3 and DU-145 cells do not express
detectable RARb, so the RARbg antagonist probably inhibits the
growth of these cells through RARg and the IC50 values observed
(75–104 nM) are close to the Kd for binding to isolated RARg
(~70 nM). The pan-RAR antagonist also inhibits growth at
concentrations (IC50 16–34 nM) close to its Kd for binding to
RARg (5 nM). These results suggest that antagonism of RARg is
sufficient to compromise survival and growth, at least of PC-3 and
DU145 cells. The RARa-selective antagonist AGN194301 only
inhibited colony formation at concentrations (~200 nM) much
higher than its Kd for binding to RARa (3 nM), and it has far too
low an affinity for RARg for this to be its target. 
Information on the influence of RARs in controlling the growth
of prostate cells has come from studies of the RAR-null mice
(Lohnes et al, 1993; Lufkin et al, 1993). Mature RARg-null mice
show atrophy and squamous metaplasia of the prostate and seminal
vesicles (Lohnes et al, 1993), whereas the RARa-null mouse shows
no such defects (Lufkin et al, 1993). The prostates of normal mice
contain only RARg, and RARa and RARb did not appear in the
RARg-null prostates. These results demonstrate the need for RAR
function in the prostate, which is fulfilled by RARg in the mouse.
Taken together, the mouse studies and our observations suggest that
RARg-regulated gene transcription is necessary for the survival and
maintenance of normal prostate epithelium in both mouse and
human. Our studies using serum-free grown cells suggest that a
basal or very low level of RARg-mediated transcription is impor-
tant to cell survival. Like other RARg-directed antagonists and
inverse agonists, AGN194310 probably represses basal levels of
receptor-mediated transcription by increasing association between
RARg and the nuclear co-repressor N-CoR (Klein et al, 2000). 
Treatment of LNCaP cells with the pan-RAR antagonist
AGN194310 led to apoptosis, as does treatment with the RAR
agonists ATRA (Gao et al, 1999) and fenretinide (Pienta et al,
1993). That both agonists and antagonists may induce apoptosis
via RARs suggests that a particular level of RAR-mediated tran-
scriptional activity may be essential for cell survival; and that
disturbing this balance in either direction may result in cell death.
Alternatively, RAR antagonists are active at concentrations close
to their Kd values, whereas growth inhibition by agonists requires
amounts that are >100´ greater than their Kds, suggesting that
some of the effects of agonist treatment may not reflect selective
actions at RARs. Indeed, Piedrafita and Pfahl concluded that
induction of apoptosis in Jurkat cells (a T cell line) by the RARg
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Table 2 Comparison of the growth inhibitory activities (IC50) and of the
receptor affinities (Kd) of antagonists 
AGN194310 AGN194431 AGN4301
a ~ b ~ gb > g >> aa >> b/g
Kd a = 3 nM  Kd a = 300 nM Kd a = 3 nM
Cell line Receptors Kd b = 2 nM  Kd b = 6 nM Kd b = 320 nM
expressed Kd g = 5 nM Kd g = 70 nM Kd g = 7250 nM
LNCaP RAR a,b,g IC50 = 16 nM IC50 = 99 nM IC50 = 203 nM 
PC-3 RARa,g IC50 = 18 nM IC50 = 104 nM IC50 = 235 nM 
DU145 RAR a,g IC50 = 34 nM IC50 = 88 nM IC50 = 201 nM agonist CD437 is not transcriptionally mediated since levels of
apoptosis are unaffected by inhibitors of protein and of mRNA
synthesis (Piedrafita and Pfahl, 1997). Moreover, ATRA binds to and
enhances activity of the transmembrane mannose-6-phosphate/IGF-2
receptor (Kang et al, 1998a and 1998b): this might suppress cell
growth via activation of TGF-b. 
RAR antagonists were more effective than ATRA in inhibiting
the growth of all three prostate carcinoma lines grown serum-free.
However, an unidentified component of serum partially reverses
the activity of RAR antagonists. Moreover, serum-free grown
LNCaP cells produce a factor(s) that interferes with the activity of
RAR antagonists, and which also stimulates colony formation by
LNCaP cells. Thus, the inhibitory effect of RAR antagonism on
cell growth may be over-ridden by an autocrine growth-stimula-
tory loop. IGF-1 and EGF did not reverse the effect of RAR antag-
onism, so future investigations should aim to identify the
‘autocrine factor(s)’, which may limit the therapeutic effectiveness
of RAR antagonists. 
Despite this possible problem, the potency of the pan-RAR
antagonist AGN194310 against primary carcinoma cells indicates
that antagonists may be particularly useful therapeutic agents.
Human primary prostate carcinoma cells express RARa and RARg,
and occasionally RARb (Lotan et al, 2000). Moreover, Gyftopoulos
and co-workers have shown that RARa expression correlates to
some extent with tumour grade and that expression is more
profound in highly proliferative tumours (Gyftopoulos et al, 2000).
As to selecting a retinoid for possible clinical use, a pan-RAR
antagonist, such as AGN194310, may be the most effective growth
inhibitory agent if each of the RARs can functionally maintain
human prostate carcinoma cells and RARa expression is important
to proliferative status. Further information as to the effectiveness
of the AGN194310 compound against a range of patient primary
material and in vivo mouse model systems of prostate carcinoma
is important to the development of this compound. 
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